Recipharm and Adroit Science Form Collaboration
News Mar 26, 2015
Recipharm AB and Adroit Science AB have announced the formation of a new strategic collaboration. Adroit Science AB will support Recipharm’s pharmaceutical development with high quality solid state characterization services.
By combining expertise in formulation development, API development, chemical analysis and solid state characterization, both the speed and cost of development can be reduced whilst, at the same time, quality is improved.
“I am very excited about this collaboration”, says Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm. “With the addition of development services from Adroit, we will have a very competitive offering, which will help our customers to progress their projects in a highly efficient way. Adroit Science AB has fast established itself as one of the leading providers of solid state characterization services in Northern Europe. Indeed, we can offer an even better service to our customers through this collaboration, including complete development from molecule to product.”
“Adroit Science and Recipharm have already cooperated in a number of successful projects, and this formal partnership marks the logical next step in the mutual development of our strategic relationship. We are delighted to join forces with a leading CDMO like Recipharm and predict that this will bring new opportunities in worldwide customer support” remarked Hans Gredeby, CEO of Adroit Science AB.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE